Synapse Open Synapse
Biology

Hansa Biopharma taps Cradle’s AI to design next-generation autoimmune therapeutics

R&D World · · 4 min read

Hansa Biopharma, the Swedish company behind the immunoglobulin G (IgG)-cleaving enzyme imlifidase, will use the AI protein-engineering platform from Dutch-Swiss firm Cradle to design its next generation of autoimmune drug candidates, the companies announced Oct. 1.

Latest from R&D World